tetano
Editor, Senior Moderator
Int J Infect Dis. 2013 Nov 5. pii: S1201-9712(13)00313-5. doi: 10.1016/j.ijid.2013.09.021. [Epub ahead of print]
Pandemic influenza A/H1N1 2009 antibodies in the metropolitan area of Buenos Aires in Argentina.
Labato MI, Contrini MM, Lazzarini D, Campos AM, Gauna ML, Claros R, L?pez EL, Savy VL, Luna CM.
Source
Hospital de Cl?nicas "Jos? de San Mart?n", Universidad de Buenos Aires, Arenales 2557, 1? A (CP 1425), CABA, Buenos Aires, Argentina.
Abstract
OBJECTIVE:
To estimate the infection prevalence in Buenos Aires during the outbreak of pandemic influenza A/H1N1 2009 virus (A(H1N1)pdm09).
METHODS:
A(H1N1)pdm09-specific antibodies were measured by hemagglutination inhibition assay in human serum samples collected 6 months after the outbreak and before the introduction of the A(H1N1)pdm09 vaccine in Argentina. Baseline levels of cross-reactive antibodies to A(H1N1)pdm09 were determined by testing 162 serum samples collected before 2009.
RESULTS:
The overall seroprevalence of A(H1N1)pdm09 in 148 children and 429 adults [Au?1] was 28.9% (95% confidence interval (CI) 25-33%), with a 58.0% prevalence in children <19 years of age and an 18.7% prevalence in adults ≥19 years of age (p<0.001). The prevalence was 43.5% in children <5 years old and 60.6% among children aged 5-18 years. The prevalence in adults declined with increasing age: 24.9% in 19-39-year-olds, 9.7% in 40-59-year-olds, and 8.1% in those ≥60 years old. The prevalence of specific A(H1N1)pdm09 antibodies was higher compared with the baseline in children (p=0.014), adolescents (p<0.001), and adults <40 years old (p=0.017) [Au?2]. Seroprevalence in health care workers was not different from the rest of the population (13.6% vs. 19.9% [Au?3], respectively; p=0.421).
CONCLUSIONS:
The prevalence of specific A(H1N1)pdm09 antibodies was high at 28.9%. The highest prevalence was observed in children, adolescents, and young adults.
Copyright ? 2013. Published by Elsevier Ltd.
KEYWORDS:
H1N1 subtype, Influenza A virus, Prevalence, Seroepidemiological study
PMID:
24211378
[PubMed - as supplied by publisher]
http://www.ncbi.nlm.nih.gov/pubmed/24211378
Pandemic influenza A/H1N1 2009 antibodies in the metropolitan area of Buenos Aires in Argentina.
Labato MI, Contrini MM, Lazzarini D, Campos AM, Gauna ML, Claros R, L?pez EL, Savy VL, Luna CM.
Source
Hospital de Cl?nicas "Jos? de San Mart?n", Universidad de Buenos Aires, Arenales 2557, 1? A (CP 1425), CABA, Buenos Aires, Argentina.
Abstract
OBJECTIVE:
To estimate the infection prevalence in Buenos Aires during the outbreak of pandemic influenza A/H1N1 2009 virus (A(H1N1)pdm09).
METHODS:
A(H1N1)pdm09-specific antibodies were measured by hemagglutination inhibition assay in human serum samples collected 6 months after the outbreak and before the introduction of the A(H1N1)pdm09 vaccine in Argentina. Baseline levels of cross-reactive antibodies to A(H1N1)pdm09 were determined by testing 162 serum samples collected before 2009.
RESULTS:
The overall seroprevalence of A(H1N1)pdm09 in 148 children and 429 adults [Au?1] was 28.9% (95% confidence interval (CI) 25-33%), with a 58.0% prevalence in children <19 years of age and an 18.7% prevalence in adults ≥19 years of age (p<0.001). The prevalence was 43.5% in children <5 years old and 60.6% among children aged 5-18 years. The prevalence in adults declined with increasing age: 24.9% in 19-39-year-olds, 9.7% in 40-59-year-olds, and 8.1% in those ≥60 years old. The prevalence of specific A(H1N1)pdm09 antibodies was higher compared with the baseline in children (p=0.014), adolescents (p<0.001), and adults <40 years old (p=0.017) [Au?2]. Seroprevalence in health care workers was not different from the rest of the population (13.6% vs. 19.9% [Au?3], respectively; p=0.421).
CONCLUSIONS:
The prevalence of specific A(H1N1)pdm09 antibodies was high at 28.9%. The highest prevalence was observed in children, adolescents, and young adults.
Copyright ? 2013. Published by Elsevier Ltd.
KEYWORDS:
H1N1 subtype, Influenza A virus, Prevalence, Seroepidemiological study
PMID:
24211378
[PubMed - as supplied by publisher]
http://www.ncbi.nlm.nih.gov/pubmed/24211378